Analysts Set Expectations for Tourmaline Bio FY2025 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at Chardan Capital upped their FY2025 earnings estimates for shares of Tourmaline Bio in a research report issued to clients and investors on Monday, May 5th. Chardan Capital analyst D. Gataulin now forecasts that the company will earn ($3.93) per share for the year, up from their previous estimate of ($4.10). Chardan Capital has a "Buy" rating and a $70.00 price target on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Chardan Capital also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.72) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last announced its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02.

A number of other brokerages also recently issued reports on TRML. Lifesci Capital initiated coverage on Tourmaline Bio in a research report on Monday, February 24th. They set an "outperform" rating and a $58.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Tourmaline Bio in a research note on Monday. Finally, Wedbush upped their price target on Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tourmaline Bio presently has an average rating of "Buy" and an average price target of $49.33.

Tourmaline Bio Stock Performance

TRML opened at $15.39 on Thursday. The business's 50 day moving average price is $15.36 and its 200 day moving average price is $18.95. The stock has a market capitalization of $395.29 million, a PE ratio of -5.46 and a beta of 2.11. Tourmaline Bio has a one year low of $11.56 and a one year high of $29.79.

Hedge Funds Weigh In On Tourmaline Bio

Several hedge funds have recently added to or reduced their stakes in TRML. Brooklyn Investment Group purchased a new position in shares of Tourmaline Bio in the 4th quarter valued at $32,000. Tower Research Capital LLC TRC grew its holdings in shares of Tourmaline Bio by 297.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock worth $33,000 after purchasing an additional 1,232 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Tourmaline Bio during the fourth quarter worth about $47,000. Virtus ETF Advisers LLC purchased a new stake in shares of Tourmaline Bio in the 4th quarter valued at about $64,000. Finally, GAMMA Investing LLC grew its stake in Tourmaline Bio by 4,481.7% during the 1st quarter. GAMMA Investing LLC now owns 7,514 shares of the company's stock worth $114,000 after buying an additional 7,350 shares during the last quarter. 91.89% of the stock is currently owned by hedge funds and other institutional investors.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.